Who can use Truqap(Capivasertib)?

The specific medical condition the drug is approved to treat.

Indication

TRUQAP, in combination with fulvestrant, is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer. Its use is contingent upon the presence of one or more alterations in the PIK3CA, AKT1, or PTEN genes, as detected by an FDA-approved test, following disease progression on or after endocrine therapy.

Related Columns

Capivasertib(Truqap)

Used in combination with fulvestrant for the treatment of HR-positive,...

WeChat Scan
Free Inquiry

What Are the Indications of Capivasertib?

Capivasertib is a kinase inhibitor developed by AstraZeneca, which was first approved for marketing in the United States in 2023. When used in combination with fulvestrant, this medication is indicate...

Indications for Capivasertib

Capivasertib is a novel kinase inhibitor developed by AstraZeneca. It first received approval from the U.S. Food and Drug Administration (FDA) for marketing in 2023, providing a new treatment option f...

Capivasertib instructions: indications, efficacy and effects, dosage, side effects, precautions

Capivasertib(Truqap) is a targeted therapy drug mainly used for patients with specific types of breast lesions. Its indications are based on genetic test results, and the applicable population mu...

Indications of Capivasertib

Capivasertib (also known as Truqap) is an innovative drug that is widely recognized internationally, especially in the treatment of specific types of breast diseases. However, its use is not with...